Strona 3 - Najlepsi lekarze wykonujący chemioterapię przy białaczce – TOP 97 lekarzy

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr Eckhart Weidmann kieruje sektorem Hematologii w Klinice Nordwest, specjalizując się w leczeniu chorób krwi, z ponad 30-letnim doświadczeniem zawodowym.

• Jeden z najlepszych lekarzy zajmujących się chłoniakiem nieziarniczym (non-Hodgkin lymphoma)
• Profesor z bogatym doświadczeniem akademickim i klinicznym
• Koncentruje się na białaczce i innych chorobach krwi

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Wiodący izraelski specjalista w dziedzinie immunoterapii raka płuca – prof. Peled kieruje Oddziałem Onkologii Klatki Piersiowej w Centrum Onkologicznym Davidoff.

• Ekspert w dziedzinie medycyny spersonalizowanej i immuno-onkologii
• Laureat nagrody ASCO MERIT za badania nad rakiem płuca
• Przewodniczący Komitetu Wczesnego Wykrywania i Prewencji IASLC
• Ukończył szkolenie specjalizacyjne (fellowship) na Uniwersytecie Kolorado w Denver

Profesor Bosch jest światowo uznanym liderem w dziedzinie przewlekłej białaczki limfocytowej (PBL), pionierem nowych metod leczenia i technologii w chorobach hematologicznych.

• Ponad 30 lat doświadczenia w hematologii, ze specjalizacją w chłoniakach i PBL
• Prowadzi badania kliniczne od fazy 1 do fazy 3, wprowadzając nowe terapie dla pacjentów
• Kierownik Kliniki Hematologii w Instytucie Onkologii IOB oraz w Szpitalu Uniwersyteckim Vall d'Hebron
• Opublikował ponad 100 artykułów w czołowych czasopismach, takich jak The New England Journal of Medicine

Prof. Myriam Ben Arush, uznana na całym świecie specjalistka w dziedzinie Onkologii Pediatrycznej, kieruje Oddziałem Pediatrycznym w Szpitalu Dziecięcym Ruth Rappaport.

• Laureatka Nagrody Ministerstwa Zdrowia za wybitną pracę
• Odznaczona tytułem Kawalera Legii Honorowej we Francji (Chevalier de la Legion d'Honneur)
• Uznana przez Światowe Stowarzyszenie Medyczne za jedną z najbardziej troskliwych lekarek na świecie
• Członek grupy onkologii dziecięcej w USA i kilku europejskich towarzystw onkologicznych

Specjalista radioterapii, skupiony na chemioterapii białaczki – dr Drumea wnosi swoje ukierunkowane doświadczenie do Centrum Medycznego Rambam.

• Onkolog z naciskiem na precyzyjne leczenie raka
• Stosuje zaawansowane techniki radioterapii
• Pracuje w Centrum Medycznym Rambam – wiodącym izraelskim szpitalu

Jako Kierownik Instytutu Onkologii od 1994 roku, Tamar Jablonski-Perec wnosi swoje wieloletnie doświadczenie w zakresie przywództwa do chemioterapii białaczki w Centrum Medycznym Hadassah.

• Profesor Onkologii na Uniwersytecie Hebrajskim od 2006 roku
• Ukończyła stypendium w zakresie onkologii w Centrum Onkologicznym Sloan-Kettering
• Otrzymała stypendium Szkoły Medycznej Hadassah za wybitne osiągnięcia
• Członek wielu międzynarodowych stowarzyszeń badawczych ds. raka

Dr Spielberg specjalizuje się w chemioterapii białaczki w Centrum Medycznym Assuta.

• Onkohematolog, skupiający się na leczeniu nowotworów krwi
• Pracuje w jednym z wiodących ośrodków medycznych w Izraelu
• Zapewnia spersonalizowane plany leczenia dla pacjentów z białaczką

Dr. Mahmoud M. El Zembely is a pediatric oncologist and malignant hematologist. He manages acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. He treats Hodgkin and non‑Hodgkin lymphomas, nephroblastoma, neuroblastoma, and bone and liver tumors. His work includes gonadal and extragonadal germ cell tumors, rhabdomyosarcoma, and non‑rhabdomyosarcoma soft tissue sarcomas. He also cares for rare cancers and survivorship.

Accreditations: M.B.B.Ch, Assiut University, 2006. Master’s in Pediatric Oncology and Malignant Hematology, 2011. Clinical fellowship in pediatric bone marrow transplantation, Seattle Cancer Care Alliance, 2015–2017. Doctorate, 2020.

Roles: South Egypt Cancer Institute–Assiut University: Pediatric Oncology, 2008–2012. Assistant Lecturer, 2012–2019. Lecturer, 2020–2024. Shefa Al‑Orman Cancer Center, Luxor: Head of Pediatric Oncology, 2020–present.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Specjalizuje się w onkologii i radiologii w Centrum Medycznym Assuta.

• Doświadczenie w protokołach chemioterapii białaczki
• Łączy wiedzę specjalistyczną z zakresu onkologii i radiologii
• Prowadzi praktykę w wiodącym centrum medycznym

Ordynator Centrum Onkologii w Centrum Medycznym Assuta – lider w opiece onkologicznej, ze szczególnym uwzględnieniem leczenia białaczki.

• Onkolog specjalizujący się w protokołach chemioterapii
• Zajmuje się złożonymi przypadkami białaczki w centrum medycznym najwyższej klasy
• Kieruje programami leczenia Centrum Onkologii